LENZ Therapeutics Stock Is Attractive Before PDUFA

Group 1 - LENZ Therapeutics, Inc. (NASDAQ: LENZ) has made steady progress towards its first approval since August, when it was previously rated as a BUY [1] - The stock price of LENZ nearly doubled in November but has since decreased significantly [1] Group 2 - Total Pharma Tracker offers tools for DIY investors, including a software that provides extensive curated research material for any ticker [3] - The platform also provides hands-on support from in-house experts who identify the best investable stocks along with buy/sell strategies and alerts [3]